FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2089888179> ?p ?o ?g. }

• W2089888179 endingPage "S21" @default.
• W2089888179 startingPage "S21" @default.
• W2089888179 abstract "We reviewed 276 patients (pt) with histologically confirmed SCLC in a single institution from January 1981 to May 1992. They were treated with three different combination chemotherapy regimens. Among 251 evaluable patients only 18 (7.17%) were alive after two years (y). All these patients were men with a median age of 59 y. All but four had Limited Disease (LD). Four patients were treated with ECCP regimen (VP16, CYC, CcNU, prednisolone), 4 with ECCA (VP-16, CYC, CcNU, ADM) and 10 with ECAP (VP-16, CYC, ADM, PCB). Among the 18 pt, 5 pt underwent chest radiotherapy and also 5 underwent prophylactic brain irradiation. Fifteen pt got a complete response (CR) and the time diagnosis-treatment was brief with a median time of 3.3 days. All the 18 pt had 0–1 ECOG performance status (PS) and most of them (15/18) a PS = 0. The 4 pt with Extensive Disease (ED) had disease in contralateral axila (1), bone and liver (1) and 2 pt were classified as ED because of exclusively having mediastinal syndrome. The median survival was 51 months (26–89 m) and, in May 1994, 9 pt were alive, 8 had died and 1 had disappeared on follow-up. Seven pt lived more than 5 y (2.78%). This results confirm that stage (LD), highPS and getting a CR are the main prognostic factors and, although relapses may exist after 2 y of survival, two-thirds of the patients being then free of disease will not relapse in the future. To find new drugs with more cytotoxic power is mandatory. We reviewed 276 patients (pt) with histologically confirmed SCLC in a single institution from January 1981 to May 1992. They were treated with three different combination chemotherapy regimens. Among 251 evaluable patients only 18 (7.17%) were alive after two years (y). All these patients were men with a median age of 59 y. All but four had Limited Disease (LD). Four patients were treated with ECCP regimen (VP16, CYC, CcNU, prednisolone), 4 with ECCA (VP-16, CYC, CcNU, ADM) and 10 with ECAP (VP-16, CYC, ADM, PCB). Among the 18 pt, 5 pt underwent chest radiotherapy and also 5 underwent prophylactic brain irradiation. Fifteen pt got a complete response (CR) and the time diagnosis-treatment was brief with a median time of 3.3 days. All the 18 pt had 0–1 ECOG performance status (PS) and most of them (15/18) a PS = 0. The 4 pt with Extensive Disease (ED) had disease in contralateral axila (1), bone and liver (1) and 2 pt were classified as ED because of exclusively having mediastinal syndrome. The median survival was 51 months (26–89 m) and, in May 1994, 9 pt were alive, 8 had died and 1 had disappeared on follow-up. Seven pt lived more than 5 y (2.78%). This results confirm that stage (LD), highPS and getting a CR are the main prognostic factors and, although relapses may exist after 2 y of survival, two-thirds of the patients being then free of disease will not relapse in the future. To find new drugs with more cytotoxic power is mandatory." @default.
• W2089888179 created "2016-06-24" @default.
• W2089888179 creator A5014973366 @default.
• W2089888179 creator A5024257182 @default.
• W2089888179 creator A5029121049 @default.
• W2089888179 creator A5039941203 @default.
• W2089888179 creator A5041617509 @default.
• W2089888179 creator A5044037201 @default.
• W2089888179 creator A5044143393 @default.
• W2089888179 creator A5048494721 @default.
• W2089888179 creator A5060323545 @default.
• W2089888179 creator A5061742108 @default.
• W2089888179 date "1995-11-01" @default.
• W2089888179 modified "2023-10-14" @default.
• W2089888179 title "94 Small cell lung cancer (SCLC) and long-survivors. A review of 276 patients (P)" @default.
• W2089888179 doi "https://doi.org/10.1016/0959-8049(95)95346-8" @default.
• W2089888179 hasPublicationYear "1995" @default.
• W2089888179 type Work @default.
• W2089888179 sameAs 2089888179 @default.
• W2089888179 citedByCount "0" @default.
• W2089888179 crossrefType "journal-article" @default.
• W2089888179 hasAuthorship W2089888179A5014973366 @default.
• W2089888179 hasAuthorship W2089888179A5024257182 @default.
• W2089888179 hasAuthorship W2089888179A5029121049 @default.
• W2089888179 hasAuthorship W2089888179A5039941203 @default.
• W2089888179 hasAuthorship W2089888179A5041617509 @default.
• W2089888179 hasAuthorship W2089888179A5044037201 @default.
• W2089888179 hasAuthorship W2089888179A5044143393 @default.
• W2089888179 hasAuthorship W2089888179A5048494721 @default.
• W2089888179 hasAuthorship W2089888179A5060323545 @default.
• W2089888179 hasAuthorship W2089888179A5061742108 @default.
• W2089888179 hasConcept C126322002 @default.
• W2089888179 hasConcept C141071460 @default.
• W2089888179 hasConcept C146357865 @default.
• W2089888179 hasConcept C151730666 @default.
• W2089888179 hasConcept C2776256026 @default.
• W2089888179 hasConcept C2776694085 @default.
• W2089888179 hasConcept C2776715498 @default.
• W2089888179 hasConcept C2779562246 @default.
• W2089888179 hasConcept C2781413609 @default.
• W2089888179 hasConcept C45393284 @default.
• W2089888179 hasConcept C500558357 @default.
• W2089888179 hasConcept C509974204 @default.
• W2089888179 hasConcept C71924100 @default.
• W2089888179 hasConcept C86803240 @default.
• W2089888179 hasConcept C90924648 @default.
• W2089888179 hasConceptScore W2089888179C126322002 @default.
• W2089888179 hasConceptScore W2089888179C141071460 @default.
• W2089888179 hasConceptScore W2089888179C146357865 @default.
• W2089888179 hasConceptScore W2089888179C151730666 @default.
• W2089888179 hasConceptScore W2089888179C2776256026 @default.
• W2089888179 hasConceptScore W2089888179C2776694085 @default.
• W2089888179 hasConceptScore W2089888179C2776715498 @default.
• W2089888179 hasConceptScore W2089888179C2779562246 @default.
• W2089888179 hasConceptScore W2089888179C2781413609 @default.
• W2089888179 hasConceptScore W2089888179C45393284 @default.
• W2089888179 hasConceptScore W2089888179C500558357 @default.
• W2089888179 hasConceptScore W2089888179C509974204 @default.
• W2089888179 hasConceptScore W2089888179C71924100 @default.
• W2089888179 hasConceptScore W2089888179C86803240 @default.
• W2089888179 hasConceptScore W2089888179C90924648 @default.
• W2089888179 hasLocation W20898881791 @default.
• W2089888179 hasOpenAccess W2089888179 @default.
• W2089888179 hasPrimaryLocation W20898881791 @default.
• W2089888179 hasRelatedWork W1993014983 @default.
• W2089888179 hasRelatedWork W2052617720 @default.
• W2089888179 hasRelatedWork W2277416945 @default.
• W2089888179 hasRelatedWork W2355670240 @default.
• W2089888179 hasRelatedWork W2357406576 @default.
• W2089888179 hasRelatedWork W2362144381 @default.
• W2089888179 hasRelatedWork W2376593068 @default.
• W2089888179 hasRelatedWork W2418514417 @default.
• W2089888179 hasRelatedWork W4291189777 @default.
• W2089888179 hasRelatedWork W1899415052 @default.
• W2089888179 hasVolume "31" @default.
• W2089888179 isParatext "false" @default.
• W2089888179 isRetracted "false" @default.
• W2089888179 magId "2089888179" @default.
• W2089888179 workType "article" @default.